Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLITOne HDM sublingual immunotherapy in pediatric atopic eczema
2008-000196-23Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Aug 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of House dust mite allergen extract in atopic dermatitis (AD), allergic rhinitis (AR) and asthma, sponsored by ALK-Abelló. Primary endpoints: Efficacy on atopic eczema severity and Patient/parent global assessment. Started Aug 2008; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
atopic dermatitis (AD)allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on 2008-000196-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000196-23.